Loomis Sayles & CO L P Protagonist Therapeutics, Inc Transaction History
Loomis Sayles & CO L P
- $72.6 Billion
- Q2 2024
Shares
2 transactions
Others Institutions Holding PTGX
# of Institutions
195Shares Held
58.7MCall Options Held
20.8KPut Options Held
109K-
Farallon Capital Management LLC San Francisco, CA5.84MShares$260 Million0.98% of portfolio
-
Black Rock Inc. New York, NY5.76MShares$257 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.29MShares$236 Million3.06% of portfolio
-
Bvf Inc San Francisco, CA3.32MShares$148 Million3.52% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.24MShares$145 Million0.0% of portfolio
About Protagonist Therapeutics, Inc
- Ticker PTGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,084,100
- Market Cap $2.19B
- Description
- Protagonist Therapeutics, Inc., a biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with...